Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

被引：8
|
作者：
Hou, Jiangxue [1 ,2 ]
Li, Yufu [1 ,2 ]
Lin, Quande [1 ,2 ]
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China
[2] Henan Canc Hosp, Zhengzhou 450008, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
关键词：
Multiple myeloma; Bispecific antibody; CAR T; Clinical trial;
D O I：
10.1186/s40164-023-00436-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by >= 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses. Here, we summarize the latest data from the 2023 ASCO annual meeting on BsAbs targeting BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 CAR T cells.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
    Chenggong Li
    Jia Xu
    Wenjing Luo
    Danying Liao
    Wei Xie
    Qiuzhe Wei
    Yinqiang Zhang
    Xindi Wang
    Zhuolin Wu
    Yun Kang
    Jin’e Zheng
    Wei Xiong
    Jun Deng
    Yu Hu
    Heng Mei
    Leukemia, 2024, 38 : 149 - 159
  • [42] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
    Li, Chenggong
    Xu, Jia
    Luo, Wenjing
    Liao, Danying
    Xie, Wei
    Wei, Qiuzhe
    Zhang, Yinqiang
    Wang, Xindi
    Wu, Zhuolin
    Kang, Yun
    Zheng, Jin'e
    Xiong, Wei
    Deng, Jun
    Hu, Yu
    Mei, Heng
    LEUKEMIA, 2024, 38 (01) : 149 - 159
  • [43] The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
    Chen, Zhaoqi
    Lu, Yang
    Xu, Yingxi
    Qiu, Shaowei
    Gu, Runxia
    Xing, Haiyan
    Tang, Kejing
    Tian, Zheng
    Rao, Qing
    Xiong, Dongsheng
    Wang, Min
    Wang, Jianxiang
    BLOOD, 2022, 140 : 7402 - 7403
  • [44] Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
    Zhang, Wenjie
    Li, Sumei
    Long, Jinlan
    Xie, Shufeng
    Wang, Minghui
    Liu, Han
    Xu, Zhenshu
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [45] CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?
    Rodriguez-Otero, Paula
    Martin, Thomas
    HEMATO, 2024, 5 (02): : 171 - 179
  • [46] Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
    Zah, Eugenia
    Nam, Eunwoo
    Bhuvan, Vinya
    Tran, Uyen
    Ji, Brenda Y.
    Gosliner, Stanley B.
    Wang, Xiuli
    Brown, Christine E.
    Chen, Yvonne Y.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [47] Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
    Eugenia Zah
    Eunwoo Nam
    Vinya Bhuvan
    Uyen Tran
    Brenda Y. Ji
    Stanley B. Gosliner
    Xiuli Wang
    Christine E. Brown
    Yvonne Y. Chen
    Nature Communications, 11
  • [48] Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)
    Maclachlan, Kylee
    Shekarkhand, Tala
    Farzana, Tasmin
    Costa, Bruno
    Firestone, Ross
    Jurgens, Eric
    Rajeeve, Sridevi
    Hashmi, Hamza
    Hassoun, Hani
    Shah, Urvi
    Hultcrantz, Malin
    Lesokhin, Alexander
    Korde, Neha
    Chung, David
    Landau, Heather
    Shah, Gunjan
    Scordo, Michael
    Giralt, Sergio
    Maura, Francesco
    Zhang, Yanming
    Cimera, Robert
    Arcila, Maria
    Tan, Carlyn
    Mailankody, Sham
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S171 - S172
  • [49] From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma
    Zhao, Jin
    Zheng, Meijing
    Ma, Li
    Guan, Tao
    Su, Liping
    HELIYON, 2024, 10 (09)
  • [50] Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting
    Kang, Yun
    Li, Chenggong
    Mei, Heng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
12345